13 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics Inc
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
in other research and development expenses, partially offset by a decrease of $4.0 million in license fees.
General and Administrative (G&A) expenses
424B5
MLYS
Mineralys Therapeutics Inc
11 Apr 24
Prospectus supplement for primary offering
4:35pm
rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our common stock, which may be offset
S-3
MLYS
Mineralys Therapeutics Inc
21 Mar 24
Shelf registration
7:30am
treaty) on gain realized upon the sale or other taxable disposition of our common stock, which may be offset by U.S. source capital losses of the Non-U.S
10-Q
3sux93
15 May 23
Quarterly report
5:25pm
8-K
EX-99.1
yruv j2hekd2qx3
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
DRS/A
eat85chx
29 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
bv3g37f
7 Dec 22
Draft registration statement (amended)
12:00am
DRS
9hufhy agl75s
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next